IRIS - Res&Arch Institutional Research Information System - Research & Archive

CHIARI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.252
AS - Asia 707
EU - Europa 652
SA - Sud America 114
Continente sconosciuto - Info sul continente non disponibili 86
AF - Africa 23
Totale 2.834
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.201
SG - Singapore 297
IT - Italia 174
CN - Cina 129
IE - Irlanda 125
VN - Vietnam 94
BR - Brasile 86
HK - Hong Kong 80
DE - Germania 72
RU - Federazione Russa 70
FR - Francia 52
FI - Finlandia 33
RO - Romania 29
GB - Regno Unito 25
CA - Canada 23
IN - India 23
UA - Ucraina 21
KR - Corea 14
BD - Bangladesh 12
PL - Polonia 12
SE - Svezia 10
AR - Argentina 9
IQ - Iraq 9
JP - Giappone 9
TR - Turchia 8
MX - Messico 7
EC - Ecuador 6
MA - Marocco 6
CH - Svizzera 5
CL - Cile 5
ZA - Sudafrica 5
JO - Giordania 4
LT - Lituania 4
PR - Porto Rico 4
VE - Venezuela 4
AT - Austria 3
CR - Costa Rica 3
ES - Italia 3
ET - Etiopia 3
ID - Indonesia 3
NL - Olanda 3
OM - Oman 3
PK - Pakistan 3
SA - Arabia Saudita 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BE - Belgio 2
BO - Bolivia 2
DZ - Algeria 2
EG - Egitto 2
EU - Europa 2
GT - Guatemala 2
HN - Honduras 2
NI - Nicaragua 2
NP - Nepal 2
SV - El Salvador 2
UZ - Uzbekistan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
CW - ???statistics.table.value.countryCode.CW??? 1
GP - Guadalupe 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
KH - Cambogia 1
KZ - Kazakistan 1
ME - Montenegro 1
MT - Malta 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
Totale 2.751
Salva come PNG Salva come JPEG
Città #
Singapore 218
Chandler 164
Dublin 125
San Jose 121
Ashburn 93
Hong Kong 80
Perugia 66
San Mateo 66
Dong Ket 44
Santa Clara 40
Beijing 37
Boardman 35
Council Bluffs 35
Altamura 33
Bucharest 28
Munich 28
Princeton 27
Medford 24
Lawrence 23
Moscow 23
Houston 21
Ho Chi Minh City 20
Lauterbourg 20
Los Angeles 20
Helsinki 17
New York 16
Chicago 15
Dallas 15
Seoul 14
Andover 13
The Dalles 13
Wilmington 13
Frankfurt am Main 11
Jacksonville 10
North Bergen 10
Nuremberg 10
Redmond 10
San Paolo di Civitate 9
Warsaw 9
Ann Arbor 8
Hanoi 8
Stockholm 8
Tokyo 8
Phoenix 7
São Paulo 7
Atlanta 6
Brooklyn 6
Des Moines 6
Falkenstein 6
Rome 6
Saint Petersburg 6
Turku 6
Calgary 5
Curitiba 5
Denver 5
Dhaka 5
Ottawa 5
Rio de Janeiro 5
Amman 4
Baghdad 4
Erbil 4
Mexico City 4
Milan 4
Mumbai 4
Nanjing 4
New Delhi 4
Orem 4
Poplar 4
Seattle 4
Bắc Ninh 3
Caracas 3
Chennai 3
Columbus 3
Guayaquil 3
Johannesburg 3
Manassas 3
Manchester 3
Montreal 3
Norwalk 3
Piscataway 3
Redwood City 3
San Francisco 3
San José 3
Toronto 3
Bexley 2
Boston 2
Brasília 2
Brussels 2
El Paso 2
Goiânia 2
Guatemala City 2
Hamilton 2
Hefei 2
Hải Dương 2
Indianapolis 2
Istanbul 2
Jeddah 2
Kanpur 2
Kansas City 2
London 2
Totale 1.815
Salva come PNG Salva come JPEG
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 206
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 137
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 133
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 133
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 131
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 129
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 126
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 121
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 119
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 117
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 116
Osimertinib 106
Validity of ICD-9-CM codes for breast, lung and colorectal cancers in three Italian administrative healthcare databases: a diagnostic accuracy study protocol 103
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 102
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 101
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 100
Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types 99
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications 97
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 93
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 90
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 90
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 90
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 89
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 79
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 64
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression 63
Totale 2.834
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.219
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022197 0 0 0 0 1 2 2 66 30 21 34 41
2022/2023482 26 109 5 39 37 42 0 30 175 0 15 4
2023/2024192 11 12 9 8 0 2 55 1 8 4 43 39
2024/2025373 10 29 41 7 39 24 9 35 68 22 57 32
2025/2026944 58 63 46 126 158 85 144 49 104 76 24 11
2026/2027276 13 35 61 145 22 0 0 0 0 0 0 0
Totale 2.834